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Equine Arteritis Virus Uses Equine CXCL16 as an Entry Receptor
Sanjay Sarkar,a Lakshman Chelvarajan,a Yun Young Go,a* Frank Cook,a Sergey Artiushin,a Shankar Mondal,a Kelsi Anderson,a
John Eberth,a Peter J. Timoney,a Theodore S. Kalbfleisch,b Ernest Bailey,a Udeni B. R. Balasuriyaa
Department of Veterinary Science, Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, Kentucky, USAa; Center for Environmental Genomics and
Integrative Biology, University of Louisville, Louisville, Kentucky, USAb
ABSTRACT
Previous studies in our laboratory have identified equine CXCL16 (EqCXCL16) to be a candidate molecule and possible cell en-
try receptor for equine arteritis virus (EAV). In horses, the CXCL16 gene is located on equine chromosome 11 (ECA11) and en-
codes a glycosylated, type I transmembrane protein with 247 amino acids. Stable transfection of HEK-293T cells with plasmid
DNA carrying EqCXCL16 (HEK-EqCXCL16 cells) increased the proportion of the cell population permissive to EAV infection
from <3% to almost 100%. The increase in permissiveness was blocked either by transfection of HEK-EqCXCL16 cells with
small interfering RNAs (siRNAs) directed against EqCXCL16 or by pretreatment with guinea pig polyclonal antibody against
EqCXCL16 protein (Gp anti-EqCXCL16 pAb). Furthermore, using a virus overlay protein-binding assay (VOPBA) in combina-
tion with far-Western blotting, gradient-purified EAV particles were shown to bind directly to the EqCXCL16 protein in vitro.
The binding of biotinylated virulent EAV strain Bucyrus at 4°C was significantly higher in HEK-EqCXCL16 cells than nontrans-
fected HEK-293T cells. Finally, the results demonstrated that EAV preferentially infects subpopulations of horse CD14 mono-
cytes expressing EqCXCL16 and that infection of these cells is significantly reduced by pretreatment with Gp anti-EqCXCL16
pAb. The collective data from this study provide confirmatory evidence that the transmembrane form of EqCXCL16 likely plays
a major role in EAV host cell entry processes, possibly acting as a primary receptor molecule for this virus.
IMPORTANCE
Outbreaks of EVA can be a source of significant economic loss for the equine industry from high rates of abortion in pregnant
mares, death in young foals, establishment of the carrier state in stallions, and trade restrictions imposed by various countries.
Similar to other arteriviruses, EAV primarily targets cells of the monocyte/macrophage lineage, which, when infected, are be-
lieved to play a critical role in EVA pathogenesis. To this point, however, the host-specified molecules involved in EAV binding
and entry into monocytes/macrophages have not been identified. Identification of the cellular receptors for EAV may provide
insights to design antivirals and better prophylactic reagents. In this study, we have demonstrated that EqCXCL16 acts as an
EAV entry receptor in EAV-susceptible cells, equine monocytes. These findings represent a significant advance in our under-
standing of the fundamental mechanisms associated with the entry of EAV into susceptible cells.
Equine arteritis virus (EAV) is a single-stranded, positive-senseRNA virus in the family Arteriviridae, genus Arterivirus, order
Nidovirales. Besides EAV, the family Arteriviridae contains four
other viruses: porcine reproductive and respiratory syndrome vi-
rus (PRRSV), simian hemorrhagic fever virus (SHFV), lactate de-
hydrogenase-elevating virus (LDV) of mice, and wobbly possum
disease virus (WPDV), which is the most recently identified mem-
ber of the Arteriviridae (1–3). Arteriviruses primarily target
monocyte/macrophage lineage cells in their respective hosts, with
disease outcomes being highly variable, in that they range from
persistent asymptomatic infections to respiratory disease, repro-
ductive failure (abortion), and even fatal hemorrhagic fever (4–7).
EAV is the causative agent of equine viral arteritis (EVA) in horses,
in which clinical signs can range from an asymptomatic infection
to a flu-like illness in adult horses, abortion in pregnant mares,
and interstitial pneumonia in neonatal foals (8, 9). Furthermore,
in a variable percentage of stallions (10 to 70%), EAV can establish
persistent infection in the reproductive tract, from which it is shed
in semen for extended periods of time; carrier stallions are widely
accepted to be the natural reservoir of the virus (9, 10). EAV in-
fects equine endothelial cells, monocytes, macrophages, and a
small subpopulation of CD3 T cells (11–13). In addition, the
virus can replicate in a number of other mammalian cell types
(including some human cells), suggesting that it may be capable of
using more than one receptor molecule to gain entry into cells
(13).
In general, the process of viral entry into target cells is initiated
by binding to a specific host cell receptor molecule(s) on the
plasma membrane (14–18). This interaction is a major determi-
nant of viral tropism and pathogenesis. Currently, the cellular
receptor(s) for EAV is not known, although previous studies have
implicated the involvement of a heparin-like molecule in bind-
ing to rabbit kidney (RK-13) cells (19, 20). Interestingly, a
recent genome-wide association study (GWAS) identified a re-
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gion in equine chromosome 11 (ECA11; positions 49572804 to
49643932) with potential involvement in EAV infection and
pathogenesis (8). Several genes within this region (e.g., CXCL16,
HRNE, RABEP1, ARRB2) have structural properties that could
enable them to participate in either the cell surface attachment or
endocytosis of EAV. However, pathway analysis using Ingenuity
Pathway Analysis (Ingenuity Systems Inc., Redwood City, CA) soft-
ware and the PANTHER classification system (www.pantherdb.org)
revealed that one of the candidate receptor molecules, equine CXCL
16 (EqCXCL16), has scavenger receptor properties in common
with CD163, an entry receptor of PRRSV (11, 14, 21, 22).
Although the molecules are not structurally identical (23), the
utilization of functionally comparable membrane-associated
proteins by EAV and PRRSV represents a potentially interesting
parallel between these two very closely related viruses, and as such,
we hypothesized that EqCXCL16 could be one of the cellular
receptors for EAV. This equine molecule has not been studied
extensively; however, there is a considerable amount of
published information concerning human CXCL16 (huCXCL
16) (24, 25), which is a member of the CXC chemokine family.
The human variant of this protein (huCXCL16) possesses a single
transmembrane domain along with an intracellular SH2 binding
domain and is expressed in both membrane-bound and soluble
forms (26, 27). While soluble huCXCL16 can function as a
chemokine, the membrane-bound form has scavenger receptor
activity for phosphatidylserine and oxidized lipoprotein (
SR-PSOX) (26, 28, 29). huCXCL16 is also involved in viral
infections, arthritis, atherosclerosis, and the metastasis of certain
cancers (25, 26, 30, 31). The in silico analysis outlined in this report
indicated that EqCXCL16 has a structural organization and
functional properties very similar to those of its human
counterpart, including the existence of membrane-bound and
soluble forms. In this study, we unequivocally confirm that the
transmembrane form of EqCXCL16 functions as a cellular
receptor for initiating EAV infection in susceptible cell types.
MATERIALS AND METHODS
Cells. Equine pulmonary artery endothelial cells (EECs) were maintained
in Dulbecco’s modified Eagle’s medium (DMEM; Mediatech, Herndon,
VA) with sodium pyruvate, 10% fetal bovine serum (FBS; HyClone Lab-
oratories, Inc., Logan, UT), 100 U/ml of penicillin, 100 g/ml streptomy-
cin, and 200 mM L-glutamine (32–34). High-passage-number rabbit kid-
ney cells (HP-RK-13 [KY] P399-409 cells; originally derived from CCL-37
cells [American Type Culture Collection {ATCC}, Manassas, VA]) and
baby hamster kidney (BHK-21) cells (CCL-10; ATCC) were propagated in
Eagle’s minimal essential medium with 10% ferritin-supplemented bo-
vine calf serum (HyClone Laboratories, Inc., Logan, UT), 100 U/ml of
penicillin, and 100 g/ml of streptomycin (Gibco, Carlsbad, CA). Human
embryonic kidney (HEK-293T) cells (CRL-3216; ATCC) were propa-
gated in DMEM with 10% ferritin-supplemented bovine calf serum (Hy-
Clone Laboratories, Inc., Logan, UT) and 100 U/ml of penicillin and 100
g/ml streptomycin (Gibco, Carlsbad, CA).
Viruses. Two strains of EAV, the virulent Bucyrus strain (VBS; VR-
796; ATCC) (5, 6) and recombinant EAV VBS expressing mCherry (EAV
sVBSmCherry) (35), were used in this study. Both viruses were propa-
gated in EECs to generate high-titer working stocks as previously de-
scribed (36, 37). Briefly, EECs infected with each virus were frozen
at 80°C when a 90 to 100% cytopathic effect (CPE) was observed. Cell
lysates were clarified by centrifugation (500  g) at 4°C for 15 min, fol-
lowed by ultracentrifugation (Beckman Coulter, Miami, FL) at 121,600 
g through a 20% sucrose cushion in NET buffer (150 mM NaCl, 5 mM
EDTA, 50 mM Tris-HCl, pH 7.5) at 4°C for 4 h to pellet the virus. Purified
preparations of each strain of EAV were resuspended in phosphate-buff-
ered saline (PBS; pH 7.4) and frozen at 80°C. Virus stocks were titrated
by standard plaque assay in RK-13 cells, and titers were expressed as the
number of PFU per milliliter (38).
Horses. Horses used for collection of blood samples were maintained
at pasture on the University of Kentucky Department of Veterinary Sci-
ence’s Main Chance Farm, Lexington, KY. Blood samples were collected
aseptically using Vacutainer tubes containing anticoagulant. This study
was performed in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National Research
Council (39). The animal protocol involving horses was approved by the
University of Kentucky Institutional Animal Care and Use Committee
(IACUC; protocol number 2013-1098).
Sequencing of equine CXCL16 gene. DNA samples from a Thor-
oughbred horse (horse TB10) and a standardbred horse (horse ST22),
identified for the susceptibility of their CD3 T cells to in vitro infection
with EAV, were isolated for sequencing. Briefly, genomic DNA (gDNA)
was obtained from purified peripheral blood mononuclear cells (PBMCs)
from each animal using a Puregene whole-blood extraction kit (Qiagen,
Valencia, CA) following the manufacturer’s instructions. DNA quality
and concentration were assessed using a NanoDrop spectrophotometer
(Thermo Scientific, Wilmington, DE) at an absorbance ratio of the optical
density (OD) at 260 nm (OD260)/OD280. Approximately 6 g of gDNA
from each animal was sent to BGI Americas (Davis, CA) for library con-
struction and sequencing. Libraries with 500-bp inserts were prepared
and sequenced as paired-end reads on an Illumina HiSeq 2000 sequencer
(2 times 100-bp sequences) to generate coverage of approximately 30
times. Reads were mapped to the horse genome reference sequence (Ecab
2.0) using CLC Workbench (version 8.0.1; CLC bio, Boston, MA). Con-
sensus sequences for each horse were analyzed for the EqCXCL16 anno-
tated gene using the reference sequence.
Cloning and expression of EqCXCL16 in Escherichia coli. Primers
for the cloning of native equine CXCL16 were designed by use of the
Primer (version 3) program and the horse genome sequences obtained as
part of this study. The sequence encoding the entire EqCXCL16 without
the first 16 amino acid residues from the signal sequences was amplified
from cDNA made from mRNA extracted from equine monocytes using a
Smart cDNA synthesis kit (Clontech Laboratories Inc., Mountain View,
CA). The cDNA amplification was carried out according to a standard
laboratory PCR protocol using forward primer cx16-15F (5=-GCGCTCG
AGGCGTTGCTGACTCTGCAAGG-3=) and reverse primer cx16-15R
(5=-GCGGATCCGCACTGCCACTGTAACTGAT-3=) (IDT, Coralville,
IA). For cloning purposes, the forward and the reverse primers were
flanked with XhoI and BamHI restriction endonuclease recognition se-
quences, respectively, which are underlined in the sequences given above.
The amplified EqCXCL16 fragment (amino acids [aa] 17 to 247) was run
on a 1% agarose gel (E-Gel EX; Life Technologies, Grand Island, NY) and
purified with a commercial kit (Zymoclean gel recovery kit; Zymo Re-
search, Irvine, CA). The purified EqCXCL16 fragment was digested with
the XhoI and BamHI restriction enzymes and ligated (Rapid DNA ligation
kit; Thermo Scientific, Rockford, IL) into the bacterial expression vector
pET15b (EMD Millipore Novagen, Temecula, CA) following digestion
with the same restriction enzymes. The resultant plasmid construct (p15-
16A) was used to transform E. coli NovaBlue (EMD Millipore Novagen,
Temecula, CA) using a TransformAid kit (Thermo Scientific, Rockford,
IL). Recombinant plasmid p15-16A (aa 17 to 247) was isolated from am-
picillin-resistant clones using a ZR plasmid miniprep kit (Zymo Research,
Irvine, CA). In order to express recombinant protein, the plasmid was
transformed into E. coli BL21(DE3) cells (EMD Millipore Novagen, Te-
mecula, CA). For large-scale EqCXCL16 protein (aa 17 to 247) produc-
tion, 500-ml cultures of E. coli BL21(DE3)/p15-16A were grown overnight
at 37°C in MagicMedia medium supplemented with 50 g/ml ampicillin.
Following centrifugation at 6,000  g for 15 min, the cell pellet was resus-
pended in buffer A (50 mM sodium phosphate, 6 M guanidine-HCl, 300
mM NaCl, pH 7.0) and subjected to several short cycles of sonication to
EAV Entry Receptor
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reduce viscosity. The lysate was centrifuged at 16,000  g for 30 min to
remove the debris. The His-tagged recombinant EqCXCL16 protein (aa
17 to 247) was purified from the supernatant by affinity chromatography
using Talon Superflow metal affinity resin (Clontech Laboratories Inc.,
Mountain View, CA) in combination with a fast performance liquid chro-
matography apparatus (Amersham Pharmacia Biotech Inc., Piscataway,
NJ). The columns were equilibrated and washed with buffer A, while
proteins were eluted using buffer B (45 mM sodium phosphate, 5.4 M
guanidine-HCl, 270 mM NaCl, 150 mM imidazole, pH 7.0). Eluted re-
combinant protein was dialyzed against PBS using Slide-A-Lyser dialysis
cassettes (Thermo Scientific, Rockford, IL). The purity and integrity of
recombinant EqCXCL16 (aa 17 to 247) were evaluated by subjecting it to
electrophoresis on a 4 to 20% gradient gel-SDS followed by staining with
Coomassie brilliant blue solution (Bio-Rad Laboratories, Hercules, CA).
The protein concentration was determined with a bicinchoninic acid
(BCA) protein assay (Thermo Scientific, Rockford, IL), using bovine se-
rum albumin as the standard.
Generation of antibodies (Abs) to EqCXCL16. Protein-specific rab-
bit antipeptide sera to EqCXCL16 were generated by immunizing rabbits
with two synthetic peptides. Specifically, the nucleotide sequence of
EqCXCL16 was used to deduce the amino acid sequence of the protein.
Peptides were designed according to the predicted antigenic regions of
EqCXCL16 using Thermo Scientific Antigen Profiler software (Thermo
Scientific, Rockford, IL) and the Geneious (version 6.1.4) program (Bio-
matters Ltd., Auckland, New Zealand). One peptide (peptide A; 39-RFPS
DSPPAVHIMKHFRK-56; Fig. 1A) was located within the amino-termi-
nal ectodomain of the EqCXCL16 protein, whereas the other peptide
(peptide B; 174-HSLVSGPEAGENQKQLKEHV-193; Fig. 1A) was lo-
cated toward the end of the ectodomain. Adult New Zealand White rab-
bits were immunized with keyhole limpet hemocyanin (KLH)-conjugated
synthetic peptide antigens according to a standard immunization proto-
col. Two New Zealand White rabbits were immunized per peptide (rab-
bits PA7505 and PA7506 for peptide A and rabbits PA7509 and PA7510
for peptide B). Each KLH-conjugated peptide (0.25 mg) was emulsified
with Freund’s complete adjuvant and administered into 4 quarter sites
intramuscularly on day 1, followed by booster immunization with 0.1 mg
of each peptide with incomplete Freund’s adjuvant on days 14, 42, 56, and
103. Serum samples were collected on day 0 (preimmunization) and on
days 28, 56, 72, and 117 postimmunization. A polyclonal antibody (pAb)
against the whole EqCXCL16 molecule minus the first 16 signal sequences
(aa 17 to 247)(Gp anti-EqCXCL16 pAb) was generated by immunization
of guinea pigs with recombinant protein expressed in E. coli. Briefly, each
guinea pig was immunized with 0.1 mg of recombinant EqCXCL16 protein
antigen emulsified with Freund’s complete adjuvant at 4 quarter sites intra-
muscularly on day 1, followed by booster immunizations with 50 g of re-
combinant EqCXCL16 protein with incomplete Freund’s adjuvant on days
21, 42, 62, and 90. Blood samples were collected on day 0 (preimmunization)
and on days 56 and 104 postimmunization. The rabbit antipeptide sera and
polyclonal guinea pig sera were initially tested by enzyme-linked immunosor-
bent assay (ELISA) using antigen consisting of either the respective peptides
or the EqCXCL16 recombinant protein. The antisera were further character-
ized by indirect immunofluorescence assay (IFA) and Western blot (WB)
analyses. The animal protocol involving rabbits and guinea pigs was approved
by the Thermo Scientific, Rockford, IL, IACUC (NIH OLAW assurance
number, A3669-01; USDA research license registration number, 23-R-0089;
PHS assurance number, A3669-01).
ELISA. Threefold serial dilutions (starting from 300 ng to 1 ng) of
purified recombinant EqCXCL16 protein in 0.1 M bicarbonate/carbonate
buffer, pH 9.6, were used to coat the 96-well ELISA plates (Corning,
Tewksbury, MA). The plates were incubated overnight at 4°C and washed
FIG 1 Amino acid sequence and schematic representation of the EqCXCL16 protein. (A) The amino acid sequence of the EqCXCL16 protein showing the signal
peptide, amino-terminal ectodomain, transmembrane domain, and carboxyl-terminal cytoplasmic endodomain. The two antigenic regions that were targeted
to generate EqXCXCL16 protein-specific rabbit antipeptide sera are boxed (peptide A, amino acids 39 to 56; peptide B, amino acids 174 to 193). (B) The
EqCXCL16 protein is a type I transmembrane protein that is predicted to comprise an N-terminal chemokine domain, a glycosylated (Asn-143) mucin-like stalk,
a transmembrane domain, and a carboxyl-terminal cytoplasmic domain.
Sarkar et al.
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twice with wash buffer (PBS, pH 7.4; Life Technologies, Grand Island,
NY) containing 0.05% Tween 20 (Bio-Rad, Hercules CA), and the reac-
tions were blocked with 200 l of blocking solution (5% nonfat dry milk
in wash buffer) at room temperature (RT) for 1 h. Rabbit antipeptide sera
against EqCXCL16 diluted 1:1,000 in blocking solution were added. The
plates were then incubated for 1 h at RT. Then, the plates were washed
four times in wash buffer and incubated with anti-rabbit IgG conjugated
to horseradish peroxidase (HRP) for 1 h at RT. After washing four times in
wash buffer, SureBlue tetramethylbenzidine microwell peroxidase sub-
strate (Kirkegaard & Perry, Gaithersburg, MD) was added to each well and
the plates were incubated for 30 min before the reaction was stopped with
100 l of 0.18 M sulfuric acid (Mallinckrodt, Dublin, Ireland). The OD
values at 450 and 650 nm were read using a Synergy H1MD microplate
reader (BioTek Instruments Inc., Winooski, VT), with the OD at 650 nm
of the reference sample being subtracted from the peak OD at 450 nm to
eliminate the background.
Plasmids and transient transfection. For expression of the
EqCXCL16 protein in eukaryotic cells, a codon-optimized full-length
EqCXCL16 sequence was commercially synthesized and cloned into the
pJ609 plasmid, into which the puromycin resistance gene was incorpo-
rated, by DNA2.0 (Menlo Park, CA). This molecular construct was iden-
tified as pJ609-EqCXCL16 and used to transform E. coli DH10B cells (Life
Technologies, Grand Island, NY). The recombinant plasmid DNA was
purified using a commercial kit (Plasmid Plus maxiprep kit; Qiagen, Va-
lencia, CA) for transfection of mammalian cells. The initial characteriza-
tion of the rabbit antipeptide sera and the polyclonal guinea pig sera by
IFA and WB analysis was performed in BHK-21 cells transiently trans-
fected with plasmid pJ609-EqCXCL16 or pJ609-GFP (as a negative con-
trol) DNA. Briefly, BHK-21 cells were seeded either in 8-well Thermo
Scientific Lab-Tek chamber slides (5  104 cells/well; Fisher Scientific,
Pittsburgh, PA) or in 6-well plates (1  106 cells/well) and were trans-
fected with 200 ng or 3 g of plasmid DNA per well, respectively, using the
Lipofectamine 3000 reagent (Life Technologies, Grand Island, NY) ac-
cording to the manufacturer’s recommendations. All IFA and WB assays
were performed at 24 h posttransfection.
Establishment of cells stably expressing the EqCXCL16 protein (sta-
ble HEK-EqCXCL16 cells). HEK-293T cells seeded in 6-well plates (2 
106 cells/well) were transfected with 3 g of plasmid pJ609-EqCXCL16
DNA using Lipofectamine 3000 (Life Technologies, Grand Island, NY)
following the manufacturer’s instructions. At 24 h posttransfection, the
medium was replaced with fresh medium containing 4 g/ml of puromy-
cin (Clontech Laboratories Inc., Mountain View, CA) and the cells were
incubated at 37°C in a CO2 incubator. This process of replacing the old
culture medium with fresh medium was repeated every other day until
only the puromycin-resistant colonies were selected. These puromycin-
resistant cells were cloned by limiting dilution in 96-well plates and
screened by IFA, after which clones showing the highest level of
EqCXCL16 protein expression were frozen in commercial cell-freezing
medium (Life Technologies, Grand Island, NY) and stored in liquid ni-
trogen until needed. At every 5th passage and up to the 50th serial passage,
cells were analyzed by IFA using Gp anti-EqCXCL16 pAb to confirm the
expression of EqCXCL16. All the experiments with HEK-293T cells ex-
pressing EqCXCL16 (HEK-EqCXCL16 cells) were performed within pas-
sage levels 5 to 10.
Confocal microscopy and IFA. Stable HEK-EqCXCL16 cells or tran-
siently transfected BHK-21 cells in 8-well Thermo Scientific Lab-Tek
chamber slides were washed in cold PBS (pH 7.4) and fixed in 4% para-
formaldehyde (PFA; Sigma-Aldrich, St. Louis, MO) for 30 min at RT. The
cells were then stained for confocal microscopy and IFA as described
elsewhere (40, 41). Briefly, following fixation, the cells were washed 5
times in ice-cold 10 mM glycine (Sigma-Aldrich, St. Louis, MO) in PBS,
pH 7.4 (PBS-glycine), and were then permeabilized with 0.2% saponin
(Sigma-Aldrich, St. Louis, MO) in PBS or left untreated with detergent
where examination of surface staining was required. All cells were washed
again in 10 mM PBS-glycine and blocked with 5% normal goat serum
(MP Biomedicals, Santa Ana, CA) for 30 min at RT prior to incubation
with specific primary antibodies (1:100 dilution) for 1 h at 37°C in a
humidified chamber. After washing in 10 mM PBS-glycine, the cells were
incubated with anti-rabbit or anti-guinea pig IgG secondary antibodies
conjugated with Alexa Fluor 488 (AF488; 1:200 dilution) for 1 h at 37°C in
a humidified chamber maintained in total darkness. After washing, the
slides were mounted in Vectashield mounting medium containing 4=,6-
diamidino-2-phenylindole (DAPI; Vector Laboratories, Burlingame,
CA). The slides were observed either under a Leica TSP SP5 confocal
microscope in an environmental chamber at the University of Kentucky
HSRB imaging facility or with an inverted fluorescence microscope
(ECLIPSE Ti; Nikon, Melville, NY).
SDS-PAGE and Western immunoblotting. Cells were lysed in radio-
immunoprecipitation assay (RIPA) lysis buffer (Santa Cruz Biotechnol-
ogy, Dallas, TX) containing Halt protease and phosphatase inhibitor
cocktails (Thermo Scientific, Rockford, IL). The solubilized proteins were
mixed with Pierce lane marker reducing 5 sample buffer containing 100
mM dithiothreitol (DTT; Thermo Scientific, Rockford, IL) and heated for
5 min at 95°C. Samples were resolved in an SDS-polyacrylamide gel (5%
stacking gel and 12% resolving gel) at 200 V for 45 min and then trans-
ferred onto a polyvinylidene difluoride (PVDF) membrane at 100 V for 1
h using a Trans-Blot transfer system (Bio-Rad, Hercules, CA). The mem-
brane was blocked with 5% nonfat milk powder (Bio-Rad, Hercules, CA)
in Tris-buffered saline with Tween 20 (TBS-T; 10 mM Tris-HCl [pH 7.6],
150 mM NaCl, 0.1% Tween 20) for 1 h at RT and incubated with primary
Abs (rabbit PA7506 anti-EqCXCL16 [1:500], rabbit PA7509 anti-
EqCXCL16 [1:500], mouse monoclonal anti-EAV GP5 [monoclonal an-
tibody {MAb} 6D10, 1:2,000], or guinea pig anti-EqCXCL16 polyclonal
[1:1,000] Abs) diluted in 5% bovine serum albumin (Sigma-Aldrich, St.
Louis, MO) in TBS-T overnight at 4°C. On the following day, the mem-
branes were washed with TBS-T and then incubated with anti-rabbit,
anti-mouse, or anti-guinea pig IgG, as appropriate, conjugated with HRP
(1:3,000; Cell Signaling, Danvers, MA) for 1 h at RT. The membranes were
washed again, and antibody binding was visualized with an enhanced
chemiluminescence (ECL) detection system using SuperSignal West Pico
chemiluminescent substrate (Thermo Scientific, Rockford, IL).
Deglycosylation of EqCXCL16 protein. EqCXCL16 proteins ex-
pressed in BHK-21 cells were deglycosylated using peptide-N-glycosidase
F (PNGase F; New England BioLabs, Ipswich, MA) following the manu-
facturer’s instructions. Briefly, BHK-21 cells transiently expressing
EqCXCL16 were lysed in RIPA lysis buffer at 24 h posttransfection.
Twenty micrograms of protein lysate and 1 l of 10 glycoprotein dena-
turing buffer in a 10-l total reaction volume were mixed, and the mixture
was incubated at 95°C for 5 min. After they were briefly chilled, the dena-
tured proteins were mixed with 2 l of 10 GlycoBuffer 2 (New England
Biolabs, Ipswich, MA), 2 l of 10% NP-40, and 1 l of PNGase F enzyme
in a total volume of 20 l. The mixture was incubated overnight at 37°C.
The deglycosylated protein lysates were analyzed by Western blotting us-
ing rabbit PA7509 anti-EqCXCL16 Ab.
Isolation of PBMCs and flow cytometry. Isolation of PBMCs from
the peripheral blood of horses (n  9) was performed as described previ-
ously (12) with some modifications (IACUC protocol number 2013-1098;
University of Kentucky, Lexington, KY). Briefly, blood (20 ml) was col-
lected aseptically using Vacutainer tubes containing 0.1 ml of 15% EDTA
solution (Covidien, Dublin, Ireland). PBMCs were isolated from the buffy
coat fraction by centrifugation through Ficoll-Paque Plus (Amersham
Biosciences, Piscataway, NJ) at 500  g for 30 min at 25°C. The PBMC
layer was collected and washed twice with Hanks balanced salt solution
(pH 7.4; Life Technologies, Grand Island, NY) by centrifugation at 300 
g for 10 min to eliminate the platelets. The cells were resuspended in RPMI
1640 medium with 2 mM GlutaMAX medium and 25 mM HEPES (Life
Technologies, Grand Island, NY) without FBS and counted using a
Countess automated cell counter (Life Technologies, Grand Island, NY).
PBMCs (2  106) were infected with EAV sVBSmCherry at a multiplicity
of infection (MOI) of 2.0 in a minimal volume (150 l) of serum-free
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RPMI 1640 medium in a treated cell culture plate (24 well) and incubated
at 37°C for 1 h in a CO2 (5%) incubator. The negative control was mock-
infected PBMCs, which were cultured under conditions identical to those
described above. After 1 h of incubation, prewarmed complete RPMI
1640 medium (1 ml) supplemented with 10% FBS, 50 M 2-mercapto-
ethanol, 100 U/ml penicillin, and 100 g/ml streptomycin was added to
each culture, and the plates were reincubated at 37°C in 5% CO2 for
another 36 h. PBMCs were harvested from the plates using a cell scraper,
and up to 1  106 cells in 100 l of flow buffer (PBS supplemented with
10% normal goat serum and 0.1% sodium azide) were incubated on ice
for 30 min with rabbit PA7509 anti-EqCXCL16 Ab (1:2,000 dilution). The
cells were washed and probed with anti-rabbit IgG conjugated to Alexa
Fluor 488 (Life Technologies, Grand Island, NY) for 20 min. The cells
were then washed and incubated with anti-CD14 (clone 105; Bettina
Wagner, Cornell University, Ithaca, NY) conjugated to Alexa Fluor 647
for 30 min on ice. After washing, the cells were resuspended in flow buffer
and acquisition was performed on a Sony Synergy SY3200 cell sorter sys-
tem (Sony Biotechnology, San Jose, CA). Cells were gated for monocytes
and then evaluated with two-color plots using WinList software (Verity
Software House, Topsham, ME). When monocytes were infected with
EAV sVBSmCherry, two-color plots of infected monocytes were gener-
ated using mCherry-gated cells.
FIG 2 Characterization of EqCXCL16-specific rabbit antipeptide sera and polyclonal guinea pig sera by ELISA, IFA, and WB analysis. (A) An in-house ELISA
was used to characterize the rabbit antipeptide sera generated against EqCXCL16 (Rb -EqCXCL16). Various concentrations (1 to 300 ng) of recombinant
EqCXCL16 expressed from E. coli were coated on a 96-well plate and then probed with antisera generated against peptides A and B (rabbit PA7506 anti-
EqCXCL16 and rabbit PA7509 anti-EqCXCL16, respectively). Broken lines, prebleed (Pb) sera from the respective rabbits. (B) BHK-21 cells were transiently
transfected with plasmids containing EqCXCL16 cDNA, and at 24 h posttransfection, cells were fixed in 4% PFA. Cells were stained with rabbit antipeptide sera
against EqCXCL16 protein (row a, rabbit PA7506 serum against peptide A; row b, rabbit PA7509 serum against peptide B) or Gp anti-EqCXCL16 pAb (row c)
or the corresponding prebleed sera. Cells were then stained with secondary antibody conjugated to AF488 and analyzed by inverted fluorescence microscopy. (C)
BHK-21 cells that had been transfected with either pJ609-GFP (control) or pJ609-EqCXCL16 were lysed in RIPA cell lysis buffer and were analyzed in the WB
assay using rabbit PA7506 anti-EqCXCL16 Ab (against peptide A) (a), rabbit PA7506 prebleed serum (b), rabbit PA7509 anti-EqCXCL16 serum (against peptide
B) (c), rabbit PA7509 prebleed serum (d), Gp anti-EqCXCL16 pAb (e), and guinea pig prebleed serum (f). Arrows, the presence (a, c, e) or absence (b, d, f) of
the EqCXCL16 protein in the WB membrane. (D) Protein lysates from BHK-21 cells transfected with either plasmid pJ609-GFP (control) or plasmid pJ609-
EqCXCL16 were deglycosylated using PNGase F. The protein lysates were analyzed by a WB assay using rabbit PA7509 anti-EqCXCL16 antiserum. Arrow,
EqCXCL16 bands.
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Enrichment of equine CD14 cells. CD14 monocytes were en-
riched indirectly with magnetic microbeads according to the manufactur-
er’s protocol (Miltenyi Biotec, Bergisch Gladbach, Germany). Briefly, PB-
MCs were blocked with 5% normal mouse serum (Innovative Research,
Novi, MI) and then incubated with anti-equine CD14 clone 105 conju-
gated with Alexa Fluor 647 (Bettina Wagner, Cornell University, Ithaca,
NY) for 30 min. After washing with magnetically activated cell sorting
(MACS) buffer, the cells were incubated with anti-Alexa Fluor 647 mi-
crobeads for 20 min. The cells were then washed with MACS buffer, ap-
plied to an LS column, and washed three times, and the bound CD14
cells were eluted with MACS buffer in the absence of the magnet, washed,
and counted using a Countess automated cell counter (Life Technologies,
Carlsbad, CA). The purity of the CD14 cells was confirmed by flow
cytometric analysis. These cells were used for the experiment in which the
cell surface EqCXCL16 protein was blocked using polyclonal guinea pig
antiserum (Gp anti-EqCXCL16 pAb).
Blocking cell surface EqCXCL16 by Gp anti-EqCXCL16 pAb. Ap-
proximately 1  104 stable HEK-293T cell transfectants expressing the
EqCXCL16 protein (HEK-EqCXCL16 cells) were seeded per well of a
96-well plate and incubated for 18 h at 37°C before being treated with
2-fold serial dilutions (1:10 to 1:160) of guinea pig anti-EqCXCL16
pAb. After 2 h of incubation at 37°C, the cells were infected with EAV
sVBSmCherry at an MOI of 1.0 in the presence of anti-EqCXCL16 anti-
body. At 12 h postinfection (hpi), the cells were analyzed for mCherry
expression using an inverted fluorescence microscope. Similar antibody
blocking experiments were conducted on enriched equine CD14 mono-
FIG 2 continued
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cytes; these were seeded in 96-well plates (1  104 cells/well) and incu-
bated for 24 h at 37°C. Subsequently, these cells were incubated with Gp
anti-EqCXCL16 pAb for another 2 h at 37°C before they were infected
with EAV sVBSmCherry. At 24 hpi, the cells were analyzed for mCherry
expression with an inverted fluorescence microscope.
siRNA-mediated downregulation of EqCXCL16 expression in HEK-
EqCXCL16 cells. Stable HEK-EqCXCL16 cells seeded (1  105 cells/well)
in 24-well plates were transfected with small interfering RNA (siRNA)
directed against EqCXCL16 using the Lipofectamine RNAiMax reagent
(Life Technologies, Grand Island, NY). These consisted of the following
two Silencer Select siRNA duplexes, designed using the GeneAssist cus-
tom siRNA builder (Life Technologies, Grand Island, NY): siRNA1, for
which the sense sequence was 5=-GGC CGG AGA AAA UCA GAA ATT-3=
and the antisense sequence was 5=-UUU CUG AUU UUC UCC GGC
Ctc-3=, and siRNA2, for which the sense sequence was 5=-AGA ACC UGA
UUC ACG CGA ATT-3= and the antisense sequence was 5=-UUC GCG
UGA AUC AGG UUC UTG-3=). A commercially available nonspecific
scrambled siRNA duplex was used as a negative control (Life Technol-
ogies, Grand Island, NY). At 30 h posttransfection, cells were infected
with EAV sVBSmCherry. At 18 hpi, cells were stained with Gp anti-
EqCXCL16 pAb and analyzed by fluorescence microscopy for the ex-
pression of mCherry and the EqCXCL16 protein. In a separate exper-
iment, cells stably expressing the EqCXCL16 protein were transfected
with siRNA duplexes targeting EqCXCL16 mRNA or scrambled
siRNA. At 30 h posttransfection, cells were infected with EAV sVB-
SmCherry, and after 18 h of additional incubation, the cells were lysed
in RIPA lysis buffer and analyzed for viral nonstructural protein 1
(nsp-1) expression, as well as for EqCXCL16 expression, by a WB
assay.
Virus overlay protein-binding assay (VOPBA) and far-Western
blotting. Approximately 100 g of total protein lysate from naive HEK-
293T cells or stable HEK-EqCXCL16 cells was separated in 12% SDS-
polyacrylamide gels and transferred onto a PVDF membrane for far-WB
analysis following a modification of a previously published protocol (42).
The bound proteins were then denatured and gradually renatured on the
membrane by sequential incubation with 6 M, 3 M, 1 M, and 0.1 M
guanidine-HCl in freshly prepared AC buffer (100 mM NaCl, 20 mM Tris
[pH 7.5], 10% glycerol, 0.5 mM EDTA, 0.1% Tween 20, 2% nonfat dry
milk, 5 mM DTT) for 30 min at RT or with AC buffer only in the absence
of guanidine-HCl overnight at 4°C. The membrane was blocked with 5%
nonfat dry milk in TBS-T (Tris-buffered saline with 0.1% Tween 20),
overlaid with purified wild-type EAV VBS (15 g/ml), and incubated
overnight at 4°C. On the next day, the membrane was washed vigorously
(3 washes of 10 min each) and incubated with mouse monoclonal Ab
(anti-GP5; MAb 6D10) directed against the EAV GP5 envelope glycopro-
tein. Monoclonal antibody binding was detected by the ECL detection
system using SuperSignal West Pico chemiluminescent substrate
(Thermo Scientific, Rockford, IL).
Labeling of EAV with biotin and EAV binding assay. EAV VBS was
purified by ultracentrifugation (at 121,600  g for 4 h) through a 20%
sucrose cushion, and the protein concentration was determined using a
BCA protein assay (Thermo Scientific, Rockford, IL). About 2 mg of pu-
rified EAV was biotinylated using EZ-Link sulfo-NHS-biotin (Thermo
Scientific, Rockford, IL) following the manufacturer’s protocol. Excess
unbound biotin was removed by filtering through a Zeba desalt spin col-
umn (molecular weight cutoff, 7,000; Thermo Scientific, Rockford, IL)
equilibrated in PBS (pH 7.4). Naive HEK-293T and HEK-EqCXCL16 cells
were washed in cold PBS (pH 7.4) and removed from the culture dish
using a nonenzymatic cell dissociation solution (Cellstripper; Mediatech
Inc., Manassas, VA). Cells were resuspended in cold PBS (pH 7.4) con-
taining 2% FBS (PBS-F), centrifuged at 1,000  g for 5 min at 4°C, and
incubated with biotinylated EAV at an MOI of 100 on ice for 2 h in total
darkness. Excess EAV was removed by washing 3 times in cold PBS-F.
Subsequently, the cells were stained with streptavidin-fluorescein isothio-
cyanate (FITC; 1:100) and incubated at 4°C for 30 min in total darkness.
Cells were washed in PBS-F at 1,000  g for 5 min at 4°C, transferred onto
glass microscope slides using a Shandon CytoSpin III cytocentrifuge with
a Shandon single cytofunnel with white filter cards (Thermo Scientific,
Rockford, IL), and incubated with DAPI solution to permit the visualiza-
tion of cell nuclei. Cells were then analyzed using a Nikon inverted fluo-
rescence microscope, and the percentage of cells bound to EAV was cal-
culated.
Antibodies. Mouse EAV anti-GP5 and mouse EAV anti-nsp-1 MAbs
(MAb 6D10 and MAb 12A4, respectively) have been described previously
(43, 44). Goat anti-rabbit IgG (HL)-HRP and goat anti-mouse IgG
(HL)-HRP were purchased from Cell Signaling Technology (Danvers,
MA). Goat anti-guinea pig IgG (HL)-HRP, goat anti-rabbit IgG (HL)
conjugated to Alexa Fluor 488, and goat anti-guinea pig IgG conjugated to
AF488 were purchased from Life Technologies (Grand Island, NY).
Streptavidin conjugated to FITC was purchased from Southern Biotech
(Birmingham, AL). The monoclonal anti-equine CD14 Ab (clone 105)
was purchased from Bettina Wagner (Cornell University, Ithaca, NY)
(45).
Nucleotide sequence accession numbers. The sequences of the com-
plete EqCXCL16 genes from two horses have been submitted to the Se-
quence Read Archive and can be found under BioSample/experiment
accession numbers SAMN03838869/SRX1097022 and SAMN03838868
/SRX1097492.
RESULTS
Sequencing of equine CXCL16 gene. Previous studies in our lab-
oratory have implicated an association between EqCXCL16 and
EAV during infection of CD3 T cells from some horses (11).
Therefore, we sequenced the complete EqCXCL16 gene from two
horses and found that the nucleotide sequences were identical.
The EqCXCL16 gene is located on equine chromosome 11 (ECA11),
spanning nucleotide positions 49746891 to 49750292, and is pre-
dicted to comprise 6 exons encoding a 247-amino-acid protein with
an approximate molecular mass of 27.2 kDa. As no information on
the structure of the EqCXCL16 protein was available, we analyzed
FIG 2 continued
Sarkar et al.
3372 jvi.asm.org April 2016 Volume 90 Number 7Journal of Virology
 on N
ovem







these sequences using the Simple Modular Architecture Research
Tool (SMART), a web resource (http://smart.embl.de/) for the
identification of proteins, the annotation of protein domains, and
exploration of protein domain architecture. This analysis suggested
that EqCXCL16 has an organization very similar to that of its
human counterpart (huCXCL16), in that it is predicted to
comprise a signal sequence (aa 1 to 23) along with three structural
domains that include an N-terminal ectodomain (aa 24 to 202), a
transmembrane domain (aa 203 to 224), and a C-terminal
domain (aa 225 to 247) (Fig. 1A and B). Although EqCXCL16
possesses only 54% predicted amino acid sequence identity
with huCXCL16, the projected similarities in overall domain
structure indicate that the N-terminal region probably consists
of a chemokine domain followed by a glycosylated mucin-like
stalk (Fig. 1B). Furthermore, the equine protein also likely
possesses scavenger receptor activity for phosphatidylserine
and oxidized lipoprotein (SR-PSOX)/CXC. Following analysis,
the sequences from the two horses were used in subsequent
experiments to design a codon-optimized variant of EqCXCL
16 for transfection of mammalian cell lines, to predict B-cell
epitopes (peptides A and B) for antiserum production, to
design PCR amplification primers for cloning of EqCXCL16,
and to design siRNAs.
Generation of EqCXCL16-specific antipeptide and poly-
clonal antisera. Since reagents to detect EqCXCL16 were not
available, we generated a specific antiserum by immunization of
FIG 3 Equine monocytes expressing CXCL16 were susceptible to EAV infection. (A) PBMCs (2  106) were stained with anti-CD14 antibody and rabbit PA7509
anti-EqCXCL16 serum (right) or prebleed serum (left). The plots were generated using WinList software with cells gated for monocytes on the basis of their
scatter. The upper right quadrant in the right panel shows that 36% of equine CD14 monocytes express EqCXCL16 on their surface. (B) Equine PBMCs (2 
106) were infected with EAV sVBSmCherry at an MOI of 2.0 and harvested after 36 h in culture. The cells were stained for anti-CD14 and rabbit PA7509
anti-EqCXCL16 peptide Ab. The cells were gated for monocytes (upper left) and plotted for EqCXCL16 and CD14 expression (upper right). Approximately 34%
of the cells were positive for CD14 (CD14) and EqCXCL16 (EqCXCL16) (green boxes). All the cells that were mCherry positive (15%; green box, lower left)
were also plotted for EqCXCL16 and CD14 expression (lower right), with the quadrants being in the same location that they were in the upper right panel. Of
these, 15% of mCherry-positive cells, approximately 71% of the cells, also expressed EqCXCL16. SC, scatter.
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rabbits with EqCXCL16 peptide A (aa residues 39 to 56) or peptide
B (aa residues 174 to 193) and by inoculation of guinea pigs with
recombinant EqCXCL16 antigen (aa residues 17 to 247) produced
in E. coli. These reagents were screened by ELISA using E. coli-
produced recombinant EqCXCL16 protein as the coating antigen.
Although detectable antibodies against EqCXCL16 were present
in serum collected from all rabbits at 56 days postimmunization,
the titers against peptide B were higher than those against peptide
A (Fig. 2A). Serum collected prior to the first immunization (pre-
bleed serum) produced no detectable reactions against the recom-
binant EqCXCL16 antigen (Fig. 2A). These results were corrobo-
rated using IFA and WB analysis on BHK-21 cells transiently
transfected with pJ609-EqCXCL16 (Fig. 2B, rows a and b, and C,
panels a and c). IFA and WB analysis results similar to those de-
scribed above were obtained with serum from EqCXCL16-immu-
nized guinea pigs (Fig. 2B, row c, and C, panel e). On the basis of
bioinformatics predictions of an N-linked glycosylation site at
amino acid residue 143 (Asn-143), it is considered likely that dif-
ferential glycosylation is responsible for the double band (approx-
imate molecular mass, 30 kDa) observed with all preparations of
the EqCXCL16 antiserum (Fig. 2C, panels a, c, and e). This was
confirmed by the disappearance of the upper band from the
doublet (Fig. 2D) observed following peptide-N-glycosidase F
(PNGase F) treatment of an EqCXCL16 protein lysate pro-
duced in BHK-21 cells.
Role of EqCXCL16 in EAV infection of equine monocytes. As
a prerequisite to determining if EqCXCL16 plays a role in EAV
infection, experiments were conducted to investigate if this mol-
ecule was expressed on equine monocytes, as these are one of the
major host cell targets for this virus. Flow cytometric analysis fol-
lowing dual staining of equine PBMCs with rabbit anti-
EqCXCL16 antibody (peptide B, rabbit PA7509) and antibody
against monocyte-specific marker CD14 demonstrated that both
antibodies bound to only 36% of the cells, suggesting that
EqCXCL16 is expressed by only a subpopulation of equine mono-
cytes (Fig. 3A). The specificity of these reactions was confirmed by
the fact that less than 1% of equine monocytes (Fig. 3A) bound to
prebleed serum from the same rabbit (rabbit PA7509). In subse-
quent experiments involving infection of equine PBMCs with
EAV sVBSmCherry followed by staining at 36 hpi with rabbit
anti-EqCXCL16 and anti-CD14 antibodies, it was found that
while mCherry expression was detectable in just 15% of equine
monocytes (CD14 and EAV-positive cells), 71% of these in-
fected monocytes expressed EqCXCL16 on their surface (CD14,
EAV-positive, and EqCXCL16-positive cells) (Fig. 3B). This sug-
gests a very strong association between EqCXCL16 surface expres-
sion and infection of equine CD14 monocytes by EAV.
Effect of pretreatment with Gp anti-EqCXCL16 polyclonal
antisera on EAV infection of purified equine monocytes. Since
EAV was found to preferentially infect EqCXCL16-expressing
CD14 monocytes (EqCXCL16 CD14 cells), we investigated
the effect of the Gp anti-EqCXCL16 pAb treatment on infection of
equine monocytes with EAV sVBSmCherry. Equine monocytes
enriched (85% purity) by selection with anti-CD14 anti-
body-conjugated magnetic microbeads were incubated with
Gp anti-EqCXCL16 pAb for 2 h at 37°C prior to infection with
EAV sVBSmCherry. Evaluation of mCherry expression at 24
hpi by fluorescence microscopy demonstrated a significant re-
FIG 4 Effect of polyclonal guinea pig antibody-mediated blocking on EAV infection of purified CD14 monocytes. Equine monocytes were purified, and 105
cells were plated in a 96-well plate in complete RPMI 1640 medium. After 24 h of incubation in RPMI 1640 medium, cells were further incubated either without
antibody (a) or with Gp anti-EqCXCL16 antiserum (b) for 2 h at 37°C. As a negative control, monocytes were also treated with prebleed guinea pig serum from
the same guinea pig (c). Cells were then infected with EAV sVBSmCherry, and at 24 hpi, cells were analyzed by inverted immunofluorescence microscopy for the
evaluation of mCherry expression.
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FIG 5 Establishment of the stable HEK-293T cell line expressing the EqCXCL16 protein (HEK-EqCXCL16 cells). HEK-293T cells were transfected with plasmid
pJ609-EqCXCL16 and selected by puromycin treatment. (A) Stable HEK-EqCXCL16 cells were surface stained with Gp anti-EqCXCL16 Ab (row a) or guinea pig
prebleed serum (row b) as the primary antibody and analyzed by confocal microscopy to confirm the expression of the EqCXCL16 protein. Naive HEK-293T cells
were also stained with Gp anti-EqCXCL16 Ab (row c). (B) Stable HEK-EqCXCL16 cells were lysed in RIPA cell lysis buffer, and equal amounts of lysates were
analyzed by a WB assay using Gp anti-EqCXCL16 Ab (a) or guinea pig prebleed serum (b). Arrows, the presence (a) or absence (b) of the EqCXCL16 protein in
the WB membrane.
EAV Entry Receptor
April 2016 Volume 90 Number 7 jvi.asm.org 3375Journal of Virology
 on N
ovem







duction in the number of Gp anti-EqCXCL16 pAb-treated in-
fected CD14 cells compared to the number of infected CD14
cells incubated without antibody or with preimmunization
guinea pig serum (Fig. 4). Interestingly, this observation is con-
sistent with EqCXCL16 acting as an initial receptor-binding
molecule for EAV.
Role of EqCXCL16 as the putative EAV receptor. Preliminary
results from our laboratory demonstrated that EAV infects only a
very small minority of the HEK-293T cell population (	3%). To
investigate if constitutive expression of the EqCXCL16 mole-
cule could increase the susceptibility of HEK-293T cells to in-
fection with EAV, we first established a stable cell line express-
ing EqCXCL16. The HEK-293T cells were transfected with
pJ609-EqCXCL16 plasmid DNA, and stable transfectants
(HEK-EqCXCL16 cells) were selected using puromycin and
analyzed for EqCXCL16 expression using confocal microscopy
and WB analysis with Gp anti-EqCXCL16 pAb. Confocal mi-
croscopy revealed that the stably transfected HEK-293T cells
expressed EqCXCL16 on the outer plasma membrane. This
conclusion was arrived at on the basis of the fact that the cells
were not permeabilized by detergent treatment during the stain-
ing procedure (Fig. 5A, row a). In contrast, HEK-EqCXCL16 cells
did not show any staining with prebleed serum from the same
guinea pig (Fig. 5A, row b), demonstrating the specificity of the Gp
anti-EqCXCL16 pAb reagent. Furthermore, mock-transfected
HEK-293T cells also failed to react with Gp anti-EqCXCL16 pAb
(Fig. 5A, row c). These results were confirmed by WB analysis,
where a band having an approximate molecular mass of 30 kDa,
which is the molecular mass predicted for EqCXCL16, was ob-
served, using the Gp anti-EqCXCL16 pAb, in cell lysates from
HEK-EqCXCL16 cells but not those from naive HEK-293T cells
(Fig. 5B, panel a). In contrast, there was no visible band (mo-
FIG 6 Effect of EqCXCL16 expression on EAV infection of stable HEK-EqCXCL16 cells. (A) Naive HEK-293T cells (row a) or stable HEK-EqCXCL16 cells
expressing the EqCXCL16 protein (row b) were infected with EAV sVBSmCherry at an MOI of 1.0, and at 12 hpi, the cells were fixed with 4% PFA. Cells were
analyzed by inverted immunofluorescence microscopy for mCherry expression. The same fields of cells were also analyzed by phase-contrast microcopy.
Compared to the level of mCherry expression in naive HEK-293T cells, a significant increase in the level of mCherry expression was found in the stable
HEK-EqCXCL16 cells (middle column). (B) The intensity of mCherry expression was quantitated using Nikon NIS-Elements AR (version 4.13.00) software. The
data represent the means 
 standard deviations from 3 independent experiments, and data were considered significant at a P value of 	0.001 by Student’s t test
(***).
Sarkar et al.
3376 jvi.asm.org April 2016 Volume 90 Number 7Journal of Virology
 on N
ovem







lecular mass, 30 kDa) in HEK-EqCXCL16 cell lysates stained
with the prebleed guinea pig serum (Fig. 5B, panel b). Expres-
sion of EqCXCL16 was maintained for more than 50 serial
passages (screened by IFA; data not shown), suggesting that
these equine sequences are tolerated in HEK-293T cells and not
subject to strong negative selective pressure. Following initial
characterization, HEK-EqCXCL16 cells were infected with
EAV sVBSmCherry at an MOI of 1.0. In contrast to naive HEK-
293T cells, almost all cells in the population were found to
express mCherry at 12 hpi (Fig. 6A, rows a and b). Similar
results were seen with EAV sVBSmCherry used at an MOI of
0.1 and 2.0 (data not shown). Also, the data revealed that there
was a significant difference in the intensity of mCherry expres-
sion in stable HEK-EqCXCL16 cells compared to that in naive
HEK-293T cells, suggesting an enhanced level of viral gene
expression in the stable cells (Fig. 6B). To confirm the effect of
EqCXCL16 on EAV gene expression, naive and stable cells were
infected with EAV, and at 18 hpi cells were analyzed by either
IFA or Western blot assay using virus-specific antibodies. In-
deed, the IFA data using an anti-nsp-1 MAb (MAb 12A4) dem-
onstrated a significant increase in the level of expression of
EAV nonstructural protein nsp-1 in the stable HEK-
EqCXCL16 cells (Fig. 7A, row a) compared to that in naive
HEK-293T cells infected with EAV sVBSmCherry (Fig. 7A, row
FIG 7 Effect of EqCXCL16 expression on EAV gene expression. (A) Stable HEK-EqCXCL16 cells (row a) or naive HEK-293T cells (row b) were infected with
EAV sVBSmCherry at an MOI of 1.0. At 18 hpi, cells were fixed with 4% PFA and stained with an anti-nsp-1 MAb (MAb 12A4) conjugated with AF488. Cells were
analyzed by inverted fluorescence microscopy to evaluate the expression of EAV nsp-1. There was a significant increase in the level of EAV nsp-1 expression in
stable HEK-EqCXCL16 cells compared to that in naive HEK-293T cells (middle panels and merged panels). (B) EAV sVBSmCherry-infected naive HEK-293T
cells or stable HEK-EqCXCL16 cells were lysed in RIPA lysis buffer and analyzed for expression of the nsp-1 gene using an anti-nsp-1 MAb (MAb 12A4). Arrows,
the location of the EAV nsp-1 (a) or -actin (b) protein.
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b). The WB analysis demonstrated that despite similar levels of
loading of cell lysate material in terms of actin amounts
(Fig. 7B), EAV nsp-1 was readily detectable in infected HEK-
EqCXCL16 cells but not in naive HEK-293T cells (Fig. 7B, pan-
els a and b). Collectively, these results demonstrated that the con-
stitutive expression of EqCXCL16 transformed HEK-293T cells
from predominantly nonpermissive to permissive with respect to
infection with EAV.
Anti-EqCXCL16 polyclonal antibodies block EAV infection
of HEK-EqCXCL16 cells. To investigate the potential for a direct
association between EAV and EqCXCL16, HEK-EqCXCL16 cells
were preincubated for 2 h at 37°C with 2-fold serial dilutions
(from 1:10 to 1:160) of Gp anti-EqCXCL16 pAb prior to infection
with EAV sVBSmCherry at an MOI of 1.0. Cells treated with sim-
ilar 2-fold dilutions of prebleed guinea pig sera were considered
negative controls. The outcome of this experiment confirmed that
Gp anti-EqCXCL16 pAbs blocked EAV sVBSmCherry infection in
HEK-EqCXCL16 cells, while untreated HEK-EqCXCL16 cells
could still be successfully infected with the virus (Fig. 8a to f). The
results also demonstrated that the inhibitory effect of pAb on EAV
infection was dose dependent, since after a certain dilution (1:
160), the Gp anti-EqCXCL16 pAb no longer blocked EAV infec-
tion (Fig. 8f). On the other hand, prebleed guinea pig sera could
not block EAV sVBSmCherry infection of HEK-EqCXCL16
cells (Fig. 8g to k) even at the highest concentration tested (1:10
dilution). The Gp anti-EqCXCL16 pAb mediated blocking of
cell surface EqCXCL16, and the resultant inhibition of EAV
infection strongly suggests that EqCXCL16 is a receptor for
EAV binding.
Blocking EAV replication by siRNA-mediated downregula-
tion of EqCXCL16 cell surface expression. HEK-EqCXCL16 cells
were transfected with Silencer Select siRNA duplexes (siRNA1 or
siRNA2) designed to inhibit the expression of EqCXCL16. Non-
transfected cells or HEK-EqCXCL16 cells transfected with a
scrambled siRNA served as controls (Fig. 9). At 48 h posttrans-
fection, immunofluorescence staining of cells with Gp anti-
EqCXCL16 pAb revealed that both siRNA1 and siRNA2 were
able to significantly reduce the surface expression of EqCXCL16
(Fig. 9A, rows c and d) compared with that for nontransfected and
scrambled siRNA-transfected HEK-EqCXCL16 cells (Fig. 9A,
rows a and b). More importantly, when HEK-EqCXCL16 cells
were transfected with either siRNA1 or siRNA2 for 30 h prior to
FIG 8 Effect of polyclonal antibody-mediated blocking of EqCXCL16 on EAV infection. Stable HEK-EqCXCL16 cells were treated with either DMEM (a), 2-fold
serial dilutions (from 1:10 to 1:160) of Gp anti-EqCXCL16 pAb (b to f), or prebleed guinea pig sera (g to k) for 2 h at 37°C. Cells were infected with EAV
sVBSmCherry at an MOI of 1.0 in the presence of Gp anti-EqCXCL16 pAb or prebleed guinea pig sera. At 12 hpi, cells were fixed and analyzed by inverted
fluorescence microscopy for the evaluation of mCherry expression. In the absence of antibody, stable cells infected with EAV sVBSmCherry expressed mCherry
(a), whereas antibody treatment inhibited mCherry expression (b to e). The prebleed sera, however, did not inhibit mCherry expression (g to k).
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infection with EAV sVBSmCherry, they became completely re-
fractory to virus infection, and this was clearly evident by the al-
most complete absence of detectable mCherry expression
(Fig. 9A, rows c and d). In contrast, mCherry expression was read-
ily detectable in equivalently infected nontransfected and scram-
bled siRNA-transfected HEK-EqCXCL16 cells (Fig. 9A, rows a
and b). These results were further confirmed by WB analysis using
equivalent amounts of cell lysates from HEK-EqCXCL16 cells trans-
fected with either siRNA1 or scrambled siRNA and then subsequently
infected (at 30 h posttransfection) with EAV sVBSmCherry (Fig. 9B).
In addition to an apparent reduction in EqCXCL16 expression, trans-
fection with siRNA1 almost completely eliminated EAV nsp-1 com-
pared with the amount of EAV nsp-1 in the scrambled siRNA-
transfected controls (Fig. 9B, panels a to c). Similar results were
obtained with EAV-infected HEK-EqCXCL16 cells transfected
with siRNA2 (data not shown). These experiments with siRNA
provide additional support for the concept that the presence of
EqCXCL16 is essential during early events in the EAV infection
process and that this molecule can act as a putative host cell sur-
face receptor.
Binding of EAV with EqCXCL16 in vitro. If EqCXCL16 func-
tions as a primary receptor for EAV rather than an accessory pro-
tein, there should be detectable binding with the viral envelope
glycoproteins. This possibility was investigated using a combina-
tion of the virus overlay protein-binding assay (VOPBA) and
far-WB techniques. In the far-WB technique, protein-protein in-
FIG 9 Effect of siRNA-mediated knockdown of EqCXCL16 on EAV infection. (A) Stable HEK-EqCXCL16 cells were transfected with two different siRNAs
(siRNA1[row c] and siRNA2 [row d]) directed against EqCXCL16 mRNA. Mock-transfected cells (row a) or cells transfected with scrambled siRNA (row b) were
considered negative controls. At 30 h posttransfection, cells were infected with EAV sVBSmCherry at an MOI of 1.0 for 18 h. Cells were fixed, stained with Gp
anti-EqCXCL16 pAb, and analyzed using an inverted fluorescence microscope for the evaluation of mCherry and EqCXCL16 expression. Green staining reflects
the surface expression of EqCXCL16, while red staining indicates mCherry expression. In the presence of EqCXCL16 (rows a and b), mCherry expression can be
visualized. In contrast, when cells were transfected with siRNAs, mCherry expression was suppressed (rows c and d). (B) Stable HEK-EqCXCL16 cells were
transfected with siRNA1, and at 30 h posttransfection, the cells were infected with EAV sVBSmCherry. After 18 h of incubation, the cells were lysed and analyzed
by a WB assay using nsp-1 (a), -actin (b), and rabbit anti-EqCXCL16 (c) Abs. Arrows, locations of nsp-1 (a), -actin (b), and EqCXCL16 (c).
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teractions are detected in vitro by electrophoresis followed by im-
mobilization of the prey protein on a PVDF membrane and then
incubation of the membrane with purified bait protein. Binding
interactions between these molecules can be inferred if the bait
protein (detected by protein-specific antisera) is found to occupy
the same position on the membrane as the prey protein. In our
experiments, total lysates from HEK-EqCXCL16 cells and naive
HEK-293T cells were transferred onto a PVDF membrane (prey
molecules) after protein separation by SDS-PAGE and sequen-
tially denatured and renatured on the membrane by treatment
with different concentrations of AC buffer containing guanidine-
HCl. The membranes were incubated with purified EAV (the bait
protein), which was detected using anti-GP5 MAb 6D10, which
specifically recognizes EAV envelope protein GP5. The anti-GP5
MAb reacted strongly with immobilized cell lysates from HEK-
EqCXCL16 cells but not those from naive HEK-293T cells (Fig.
10a). Moreover, the anti-GP5 MAb bound to the same position
(Fig. 10a) on the membrane where the EqCXCL16 band was de-
tected (30 kDa). For comparison, the migration of EqCXCL16
detected by the anti-EqCXCL16 pAb was shown in the same mem-
brane after anti-GP5 MAb was stripped off and the membrane was
reprobed with anti-EqCXCL16 pAb (Fig. 10c). To exclude the
possibility of nonspecific interactions between the anti-GP5 MAb
and cell lysate proteins, a control experiment in which the incu-
bation step with purified EAV was omitted was performed. In this
case, no reactivity was detected at a position corresponding to the
migration of a 30-kDa protein (Fig. 10b). These data establish the
fact that there is direct binding between the virus particle and
the EqCXCL16 protein.
EqCXCL16 can act as an EAV binding receptor rather than
an accessory molecule. To investigate if EqCXCL16 can function
as a receptor for EAV, a binding assay was performed at 4°C to
prevent viral internalization using naive HEK-293T and HEK-
EqCXCL16 cells. Stable as well as naive HEK-293T cells were in-
cubated with biotinylated EAV VBS (MOI of 100) at 4°C for 2 h,
streptavidin-FITC was added, and the cells were visualized by in-
verted fluorescence microscopy. It was found that EAV binding
was significantly higher in stable HEK-EqCXCL16 cells than naive
HEK-293T cells (Fig. 11A). The data revealed that expression of
EqCXCL16 produced a significant (P 	 0.01) increase in the level
of binding of biotinylated EAV VBS to HEK-293T cells (Fig. 11B).
This indicated that EqCXCL16 could act as a binding receptor for
EAV rather than as an accessory molecule.
DISCUSSION
Viruses utilize multiple different attachment factors, receptors,
and entry mediators to gain entry into their target host cells (46).
Although it has been demonstrated that complex interactions be-
tween the major and minor envelope proteins determine EAV
tropism (12), the host cell molecules targeted by these viral pro-
teins have not been identified. All that is known about the early
events associated with EAV infection is that virus yields are re-
duced but not eliminated by pretreatment of host cells with hepa-
rinase (19, 20) and that the virus probably enters via classical,
pH-dependent, clathrin pit-mediated endocytosis rather than by
an endocytosis-independent mechanism (46–48). In this report,
we present evidence that the transmembrane form of EqCXCL16
can function as a binding receptor for EAV. Completion of these
experiments required the development and characterization of
new reagents, including EqCXCL16-specific antisera, and estab-
lishment of a stable HEK-293T cell line (HEK-EqCXCL16 cells)
that constitutively expressed the transmembrane form of the pro-
tein. The EAV construct encoding mCherry as a reporter gene
(EAV sVBSmCherry) has been shown to have the same pheno-
typic characteristics as the parental strain EAV VBS in relation to
virus growth and cellular tropism (35).
FIG 10 Analysis of a direct in vitro interaction between purified EAV and EqCXCL16 protein by a combination of VOPBA and far-WB analysis. Stable
HEK-EqCXCL16 or naive HEK-293T cell lysates were separated on a 12% SDS-polyacrylamide gel and transferred onto a PVDF membrane. The proteins in the
membrane were denatured and renatured using sequentially decreasing concentrations of guanidine-HCl. The membranes were blocked and incubated either
with purified EAV VBS at a concentration of 15 g/ml in protein-binding buffer (a) or with protein-binding buffer only without purified EAV VBS (b). After they
were washed, the membranes were incubated with anti-GP5 MAb 6D10 and developed using the ECL method. (a) Binding of EAV VBS to the EqCXCL16 protein
(arrow). (c) Antibodies were stripped off the membrane shown in panel a and reprobed with Gp anti-EqCXCL16. As indicated by the arrow in panel c, EqCXCL16
was detected at the same position on the membrane where EAV GP5 was detected in panel a.
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Equine monocytes are one of the primary target cells during
natural EAV infection, and they play a significant role in the
pathogenesis of EVA (37). However, studies in our laboratories
have demonstrated that only a subpopulation of CD14 mono-
cytes become infected with EAV (L. Chelvarajan, Y. Y. Go, R. F.
Cook, S. P. Mondal, S. Sarkar, P. J. Henney, F. Marti, D. W. Horo-
hov, P. J. Timoney, and U. B. R. Balasuriya, submitted for publi-
cation) (12). On the basis of the results of this study, it is apparent
that a majority of EAV-infected monocytes include a subpopula-
tion that expresses EqCXCL16 (CD14 CXCL16). Furthermore,
when enriched CD14 equine monocytes were preincubated with
Gp anti-EqCXCL16 pAb, EAV infection was significantly blocked,
as evidenced by a reduction in the number of cells expressing the
mCherry protein. Collectively, these results indicate that
EqCXCL16 plays an important role during the initial stage of EAV
infection of the susceptible CD14 monocyte. This conclusion
was strongly supported by evidence obtained with HEK-293T cells
demonstrating that the constitutive expression and translocation
of EqCXCL16 to the plasma membrane (determined by confocal
microscopy) significantly enhanced the susceptibility of these hu-
man cells to infection with EAV. Moreover, this enhanced suscep-
tibility in HEK-EqCXCL16 cells was effectively eliminated both by
preincubation with EqCXCL16-specific polyclonal antisera and
by transfection with siRNAs designed to downregulate expres-
sion of this equine protein. Although these results demonstrate
that EqCXCL16 is important early in the EAV infection process,
they do not prove that the molecule functions as a cellular recep-
tor. Subsequent experimental data based on the results of VOPBA
and far-Western comparative blot analysis of cell lysates prepared
from HEK-EqCXCL16 and naive HEK-293T cells showed that
purified EAV associates directly with EqCXCL16 even when im-
mobilized on a PVDF membrane. The potential biological signif-
icance of this direct binding interaction was further strengthened
by the fact that larger amounts of biotinylated EAV remained
FIG 11 Role of EqCXCL16 in the attachment of EAV to host cells. Equal numbers (2  106) of naive HEK-293T cells or stable HEK-EqCXCL16 cells were washed
and resuspended in cold PBS (pH 7.4) in 2% FBS (PBS-F) and then incubated with biotinylated EAV-VBS on ice for 2 h in the dark. After adsorption, excess EAV
was removed by washing in cold PBS-F, and the cells were then stained with streptavidin-FITC. After 3 washings, the cells were resuspended in PBS-F, 50 l of
cells was cytospun onto a slide, and DAPI solution was added to the cells. (A) Cells were analyzed using an inverted fluorescence microscope. The green dots in
the IFA images reflect the binding of EAV-VBS. Compared to the level of binding seen in row a, row b shows a significant reduction in the level of EAV VBS
binding to naive HEK-293T cells, as indicated by fewer green dots. (B) A total of 300 cells were counted using Nikon NIS-Elements AR (version 4.13.00) software,
and the percentage of stable HEK-EqCXCL16 cells or naive HEK-293T cells that showed EAV binding was calculated. Data represent the means 
 standard
deviations, and data were considered significant at a P value of 	0.01 by Student’s t test (**).
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bound to HEK-EqCXCL16 cells than to naive HEK-293T cells
when the cells were incubated at 4°C. Taken together, these exper-
imental results are consistent with the fact that the transmem-
brane form of EqCXCL16 functions as an EAV receptor rather
than an accessory protein that helps with virus adsorption to the
cell surface. Studies performed on heparinase-treated cells (19,
20) suggest that an association with heparin is involved in infec-
tion of cells with EAV, although this probably functions as an
attachment factor mediating nonspecific interactions that facili-
tate the concentration of virus particles on the cell surface prior to
actual receptor binding. It is possible that the background levels of
biotinylated EAV VBS binding at 4°C observed in the naive HEK-
293T cells were the result of interactions with heparin sulfate.
Although EqCXCL16 may be important for EAV entry in some
cell populations, it is almost certainly not the only receptor used
by this virus. EAV has a relatively broad host cell tropism, in that it
can infect a wide variety of common laboratory cell lines, includ-
ing but not exclusively baby hamster kidney (BHK-21), African
green monkey kidney (Vero, MA-104), rabbit kidney (RK-13),
and human kidney cells (13). Obviously, these nonequine species-
derived cell lines do not express EqCXCL16. Furthermore, not all
CD14 equine monocytes that can be infected with EAV express
detectable levels of EqCXCL16, and infection of the equine mono-
cyte population is only partially blocked by preincubation with Gp
anti-EqCXCL16 pAb. These results suggest that even in the case of
equine cells, EAV can use a molecule(s) other than EqCXCL16 as
an entry receptor(s). It should be noted that the use of multiple
receptors among the arteriviruses is not without precedent, as at
least six different cellular molecules have been implicated as re-
ceptors for PRRSV (14, 49–53). These include sialoadhesin, hepa-
ran sulfate, CD151, CD163, dendritic cell-specific intercellular ad-
hesion molecule 3 grabbing nonintegrin (DC-SIGN; CD209), and
vimentin, although the first two probably function as attachment
factors rather than specific cellular receptors.
To the best of our knowledge, there have been no other de-
scriptions of CXCL16 being used as a virus host cell receptor.
Although both HIV and the severe acute respiratory syndrome
coronavirus have been reported to interact specifically with hu-
man CXCL16, these interactions influence pathogenesis rather
than determine host cell attachment (26, 54). While utilization of
the CXCL16 protein is currently unique to EAV, the use of scav-
enger receptors as host cell receptors is not. For example, studies
suggest that CD163 can act as a receptor for both PRRSV and
African swine fever virus (55, 56). Interestingly, both CD163 and
CXCL16 are type 1 membrane proteins expressed in monocytes,
macrophages, and endothelial cells (57, 58). The transmembrane
form of CD163 is cleaved by the disintegrin-like metalloprotei-
nases ADAM10 and ADAM17 (28, 59, 60). Similarly, human
CXCL16 is also cleaved by ADAM10 to release soluble chemokine.
However, the overall structure of these molecules varies consider-
ably, with CXCL16 being classified as a class G scavenger receptor
on the basis of the domain properties outlined above, whereas
CD163 is a class I scavenger receptor consisting of proline-serine-
threonine-rich (PST) domains coupled to multiple cysteine-rich
domains (23).
In summary, unequivocal evidence based on EqCXCL16 ex-
pression in a subpopulation of virus-susceptible CD14 mono-
cytes coupled with results from a comprehensive series of experi-
ments involving protein-specific antiserum and siRNA reagents
conducted in HEK-EqCXCL16 cells confirm that EAV uses
EqCXCL16 as a host cell receptor. At this stage, it is not known if
EqCXCL16 acts as a primary receptor, if it can function alone, or if
additional host cell-specified molecules are required. It is likely
that heparin sulfate may be involved as an attachment factor en-
abling the concentration of EAV particles on the cell surface. Al-
though EqCXCL16 is clearly a host cell receptor, it is almost cer-
tainly not the only receptor used by this virus.
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